CNPase Recombinant Antibody
Applications
Reactivity
| Overview | |
| Catalog # | bsm-60368m |
| Product Name | CNPase Recombinant Antibody |
| Applications |
WB
IHC-P
IHC-F
IF(IHC-P)
IF(ICC)
IF
|
| Reactivity | Human, Rat |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Mouse |
| Source | KLH conjugated synthetic peptide derived from human CNPase |
| Clonality | Recombinant |
| Isotype | IgG1/Kappa |
| Concentration | Lot Dependent |
| Purification | Purified by Protein G. |
| Storage Buffer | 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 1267 |
| Swiss Prot | P09543 |
| Subcellular location | Cytoplasm |
| Synonyms | 2',3'-cyclic-nucleotide 3'-phosphodiesterase; CNPase; Cnp; Cnp-1; Cnp1; 2''; 2'3' cyclic nucleotide 3' phosphodiesterase; 2'3'-cyclic-nucleotide 3'-phosphodiesterase; 3''-cyclic-nucleotide 3''-phosphodiesterase; CN37_HUMAN; CNP 1; CNP; CNP1. |
| Background | Predicted to enable 2',3'-cyclic-nucleotide 3'-phosphodiesterase activity. Involved in substantia nigra development. Located in several cellular components, including extracellular space; microtubule; and plasma membrane. Implicated in hypomyelinating leukodystrophy 20; multiple sclerosis; and schizophrenia. Biomarker of alcoholic liver cirrhosis; multiple sclerosis; and restless legs syndrome. [provided by Alliance of Genome Resources, Nov 2021] |
| Application Dilution | |
| WB | =1:500-2000 |
| IHC-P | ICC=1:50 |
| IHC-F | IF=1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(ICC) | 1:50-200 |
| IF | |